342 related articles for article (PubMed ID: 28407088)
41. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma.
Sakaguchi T; Satoi S; Yamamoto T; Yamaki S; Sekimoto M
Surg Today; 2020 Apr; 50(4):335-343. PubMed ID: 31993761
[TBL] [Abstract][Full Text] [Related]
42. Predicting resection margin status of pancreatic neuroendocrine tumors on CT: performance of NCCN resectability criteria.
Kim DH; Kim B; Chung DJ; Kim KA; Lee SL; Choi MH; Kim H; Rha SE
Br J Radiol; 2023 Dec; 96(1152):20230503. PubMed ID: 37750830
[TBL] [Abstract][Full Text] [Related]
43. Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria.
Hong SB; Lee SS; Kim JH; Kim HJ; Byun JH; Hong SM; Song KB; Kim SC
Radiology; 2018 Dec; 289(3):710-718. PubMed ID: 30251929
[TBL] [Abstract][Full Text] [Related]
44. Neoadjuvant chemoradiotherapy for locally advanced pancreas cancer rarely leads to radiological evidence of tumour regression.
Dudeja V; Greeno EW; Walker SP; Jensen EH
HPB (Oxford); 2013 Sep; 15(9):661-7. PubMed ID: 23458352
[TBL] [Abstract][Full Text] [Related]
45. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
[TBL] [Abstract][Full Text] [Related]
46. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review.
Gostimir M; Bennett S; Moyana T; Sekhon H; Martel G
BMC Cancer; 2016 Oct; 16(1):786. PubMed ID: 27724927
[TBL] [Abstract][Full Text] [Related]
47. Role of endoscopic ultrasound and magnetic resonance imaging in the preoperative staging of pancreatic adenocarcinoma.
Ahmad NA; Lewis JD; Siegelman ES; Rosato EF; Ginsberg GG; Kochman ML
Am J Gastroenterol; 2000 Aug; 95(8):1926-31. PubMed ID: 10950037
[TBL] [Abstract][Full Text] [Related]
48. Borderline resectable pancreatic tumors: is there a need for further refinement of this stage?
Shrikhande SV; Arya S; Barreto SG; Ingle S; D'Souza MA; Hawaldar R; Shukla PJ
Hepatobiliary Pancreat Dis Int; 2011 Jun; 10(3):319-24. PubMed ID: 21669578
[TBL] [Abstract][Full Text] [Related]
49. Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.
Schwarz L; Katz MH
Hematol Oncol Clin North Am; 2015 Aug; 29(4):727-40. PubMed ID: 26226907
[TBL] [Abstract][Full Text] [Related]
50. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer.
Yasuta S; Kobayashi T; Aizawa H; Takahashi S; Ikeda M; Konishi M; Kojima M; Kuno H; Uesaka K; Morinaga S; Miyamoto A; Toyama H; Takakura N; Sugimachi K; Takayama W
BMC Cancer; 2020 Dec; 20(1):1184. PubMed ID: 33267820
[TBL] [Abstract][Full Text] [Related]
51. Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer.
Klaiber U; Schnaidt ES; Hinz U; Gaida MM; Heger U; Hank T; Strobel O; Neoptolemos JP; Mihaljevic AL; Büchler MW; Hackert T
Ann Surg; 2021 Jan; 273(1):154-162. PubMed ID: 30921051
[TBL] [Abstract][Full Text] [Related]
52. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
[TBL] [Abstract][Full Text] [Related]
53. Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT.
Park SJ; Kim JH; Joo I; Han JK
Abdom Radiol (NY); 2021 Oct; 46(10):4765-4778. PubMed ID: 34085090
[TBL] [Abstract][Full Text] [Related]
54. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.
Gillen S; Schuster T; Meyer Zum Büschenfelde C; Friess H; Kleeff J
PLoS Med; 2010 Apr; 7(4):e1000267. PubMed ID: 20422030
[TBL] [Abstract][Full Text] [Related]
55. Treatment strategies for borderline resectable pancreatic neuroendocrine tumors: a narrative review.
Chang JY; Ruff SM; Cloyd JM
Chin Clin Oncol; 2024 Apr; 13(2):25. PubMed ID: 38711178
[TBL] [Abstract][Full Text] [Related]
56. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
57. Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Sulciner ML; Ashley SW; Molina G
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013111
[TBL] [Abstract][Full Text] [Related]
58. Applicability of current NCCN Guidelines for pancreatic adenocarcinoma resectability: analysis and pitfalls.
Garces-Descovich A; Beker K; Jaramillo-Cardoso A; James Moser A; Mortele KJ
Abdom Radiol (NY); 2018 Feb; 43(2):314-322. PubMed ID: 29392370
[TBL] [Abstract][Full Text] [Related]
59. Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society.
Yamada S; Fujii T; Takami H; Hayashi M; Iwata N; Kanda M; Tanaka C; Sugimoto H; Nakayama G; Koike M; Fujiwara M; Kodera Y
Surgery; 2017 Oct; 162(4):784-791. PubMed ID: 28655416
[TBL] [Abstract][Full Text] [Related]
60. Clinical significance of defining borderline resectable pancreatic cancer.
Kang MJ; Jang JY; Kwon W; Kim SW
Pancreatology; 2018 Mar; 18(2):139-145. PubMed ID: 29274720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
